Molecular Biology Reports

, Volume 38, Issue 2, pp 1231–1236 | Cite as

The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line

  • Katarzyna Gach
  • Janusz Szemraj
  • Anna Wyrębska
  • Anna Janecka


Matrix metalloproteinases (MMPs) are proteolytic enzymes involved in degradation of extracellular matrix, a process that initiates uncontrolled spread of proliferating cancer cells and therefore plays a crucial role in cancer invasion and metastasis. Compounds able to modulate MMP activity may become important tools in cancer research. In the present study we examined the effect of two μ-selective opioids, morphine and endomorphin-2 (EM-2) on the production of MMP-2 and MMP-9 in MCF-7 cells. We report that both opioids time- and concentration-dependently inhibited the expression and secretion of these MMPs. The observed effect was not reversed by naloxone (Nal). Further experiments showed that morphine and EM-2 decreased endothelial nitric oxide synthase (eNOS) mRNA level and nitric oxide (NO) secretion in MCF-7 cells. These findings indicate that attenuation of MMP secretion by opioids was not mediated by opioid receptors but was under the control of nitric oxide system.


Nitric oxide synthase Biochemical markers ELISA assay RT-PCR 



This work was supported by the grants from Polish Ministry of Science (No NN 401 0155 36) and the Medical University of Lodz (No 503-1156-2). The authors wish to thank Jozef Cieslak for his excellent technical assistance.


  1. 1.
    Engbring JA, Kleinman HK (2003) The basement membrane matrix in malignancy. J Pathol 200:465–470CrossRefPubMedGoogle Scholar
  2. 2.
    Wideł MS, Wideł M (2006) Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer. Postepy Hig Med Dosw 60:453–470Google Scholar
  3. 3.
    Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284:67–68CrossRefPubMedGoogle Scholar
  4. 4.
    Śliwowska I, Kopczyński Z (2005) Matrix metalloproteinases–biochemical characteristics and clinical value determination in breast cancer patients. Contemp Oncol 9:327–335Google Scholar
  5. 5.
    Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 10:7621–7628CrossRefPubMedGoogle Scholar
  6. 6.
    Lynch CC, Matrisian LM (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70:561–573CrossRefPubMedGoogle Scholar
  7. 7.
    Ramnath N, Creaven PJ (2004) Matrix metalloproteinase inhibitors. Curr Oncol Rep 6:96–102CrossRefPubMedGoogle Scholar
  8. 8.
    Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269–285CrossRefPubMedGoogle Scholar
  9. 9.
    Mook OR, Frederiks WM, Van Noorden CJ (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705:69–89PubMedGoogle Scholar
  10. 10.
    Fichna J, do-Rego JC, Chung NN, Lemieux C, Schiller PW, Poels J, Broeck JV, Costentin J, Janecka A (2007) Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), d-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), d-2-Nal(4)]endomorphin-2 (Antanal-2). J Med Chem 50:512–520CrossRefPubMedGoogle Scholar
  11. 11.
    Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159CrossRefPubMedGoogle Scholar
  12. 12.
    Winer J, Jung CK, Shackel I, Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270:41–49CrossRefPubMedGoogle Scholar
  13. 13.
    Hatzoglou A, Kampa M, Castanas E (2005) Opioid-somatostatin interactions in regulating cancer cell growth. Front Biosci 10:244–256CrossRefPubMedGoogle Scholar
  14. 14.
    Kampa M, Bakogeorgou E, Hatzoglou A, Damianaki A, Martin PM, Castanas E (1997) Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol 335:255–265CrossRefPubMedGoogle Scholar
  15. 15.
    Moncada S, Higgs A (1993) The l-arginine-nitric oxide pathway. N Engl J Med 329:2002–2012CrossRefPubMedGoogle Scholar
  16. 16.
    Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB (1998) The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19:711–721CrossRefPubMedGoogle Scholar
  17. 17.
    Pfeilschifter J, Eberhardt W, Huwiler A (2001) Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets. Eur J Pharmacol 429:279–286CrossRefPubMedGoogle Scholar
  18. 18.
    Novaro V, Pustovrh C, Colman-Lerner A, Radisky D, Lo Nostro F, Paz D, Jawerbaum A, González E (2002) Nitric oxide induces gelatinase A (matrix metalloproteinase 2) during rat embryo implantation. Fertil Steril 78:1278–1287CrossRefPubMedGoogle Scholar
  19. 19.
    Hirai Y, Migita K, Honda S, Ueki Y, Yamasaki S, Urayama S, Kamachi M, Kawakami A, Ida H, Kita M, Fukuda T, Shibatomi K, Kawabe Y, Aoyagi T, Eguchi K (2001) Effects of nitric oxide on matrix metalloproteinase-2 production by rheumatoid synovial cells. Life Sci 68:913–920CrossRefPubMedGoogle Scholar
  20. 20.
    Kampa M, Hatzoglou A, Notas G, Niniraki M, Kouroumalis E, Castanas E (2001) Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells. Cell Death Differ 8:943–952CrossRefPubMedGoogle Scholar
  21. 21.
    Harimaya Y, Koizumi K, Andoh T, Nojima H, Kuraishi Y, Saiki I (2002) Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett 187:121–127CrossRefPubMedGoogle Scholar
  22. 22.
    Shariftabrizi A, Nifli AP, Ansari M, Saadat F, Ebrahimkhani MR, Alizadeh N, Nasseh A, Alexaki VI, Dehpour AR, Castanas E, Khorramizadeh MR (2006) Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine. Eur J Pharmacol 530:33–39CrossRefPubMedGoogle Scholar
  23. 23.
    Gach K, Piestrzeniewicz M, Fichna J, Stefanska B, Szemraj J, Janecka A (2008) Opioid-induced regulation of mu-opioid receptor gene expression in the MCF-7 breast cancer cell line. Biochem Cell Biol 86:217–226CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Katarzyna Gach
    • 1
  • Janusz Szemraj
    • 2
  • Anna Wyrębska
    • 1
  • Anna Janecka
    • 1
  1. 1.Department of Biomolecular ChemistryMedical University of LodzLodzPoland
  2. 2.Department of BiochemistryMedical University of LodzLodzPoland

Personalised recommendations